Today’s guest on The Long Run is Krishna Yeshwant.
Krishna is a general partner with GV, the corporate venture firm formerly known as Google Ventures. He is a rare bird – a Stanford computer scientist and a Harvard physician. With this combination of professional interests, and with the resources of Google to invest in fledgling companies, Krishna has acquired an unusual vantage point on where things are going, and where they could go, in biotech and healthcare.
GV, like most corporate venture firms, doesn’t promote itself as much as traditional venture firms that need to hit up Limited Partners for new cash every 3-5 years. Krishna doesn’t talk to the media much. I enjoy talking with him on a semi-regular basis, and appreciate this extended look into his thinking on the podcast. He has his hands in a huge number of pies in biopharma, in genomic diagnostics, and in biology-and-healthcare software.
Krishna recently turned 40, a traditional time to take stock on one’s work.
Here’s one safe bet: He will be around a long time, keeping his finger on the pulse of biology and computing.
Before we dive in, a word from our sponsor.
YEAH! You heard that right! <fist pump> The Long Run now has a new marquee sponsor: PPD Biotech.
So, back to that brief word from our sponsor:
As your drug development advances, it’s critical to select the right CRO partner for your innovative therapy. With a full set of development services and global reach, PPD Biotech offers teams that are dedicated to biotech and small pharma.
PPD Biotech knows that every milestone, every project update, every change in direction is important. Committed to close alignment and cultural fit, PPD Biotech works as an extension of your team every step of the way to find innovative solutions that get your treatments to the clinic faster.
To learn more about PPD Biotech or to schedule a meeting with us at the upcoming J.P. Morgan conference, visit www.PPDbiotech.com/longrun.
Now, join me and Krishna Yeshwant for another episode of The Long Run.